Our Parkinson's Place: Parkinson’s startup Prevail raises $75M for gene therapy programs

I HAVE PARKINSON'S DISEASES AND THOUGHT IT WOULD BE NICE TO HAVE A PLACE WHERE THE CONTENTS OF UPDATED NEWS IS FOUND IN ONE PLACE. THAT IS WHY I BEGAN THIS BLOG.

I COPY NEWS ARTICLES PERTAINING TO RESEARCH, NEWS AND INFORMATION FOR PARKINSON'S DISEASE, DEMENTIA, THE BRAIN, DEPRESSION AND PARKINSON'S WITH DYSTONIA. I ALSO POST ABOUT FUNDRAISING FOR PARKINSON'S DISEASE AND EVENTS. I TRY TO BE UP-TO-DATE AS POSSIBLE.

I AM NOT RESPONSIBLE FOR IT'S CONTENTS. I AM JUST A COPIER OF INFORMATION SEARCHED ON THE COMPUTER. PLEASE UNDERSTAND THE COPIES ARE JUST THAT, COPIES AND AT TIMES, I AM UNABLE TO ENLARGE THE WORDING OR KEEP IT UNIFORMED AS I WISH. IT IS IMPORTANT TO UNDERSTAND I AM A PERSON WITH PARKINSON'S DISEASE. I HAVE NO MEDICAL EDUCATION,

I JUST WANT TO SHARE WITH YOU WHAT I READ ON THE INTERNET. IT IS UP TO YOU TO DECIDE WHETHER TO READ IT AND TALK IT OVER WITH YOUR DOCTOR. I AM JUST THE COPIER OF DOCUMENTS FROM THE COMPUTER. I DO NOT HAVE PROOF OF FACT OR FICTION OF THE ARTICLE. I ALSO TRY TO PLACE A LINK AT THE BOTTOM OF EACH ARTICLE TO SHOW WHERE I RECEIVED THE INFORMATION SO THAT YOU MAY WANT TO VISIT THEIR SITE.

THIS IS FOR YOU TO READ AND TO ALWAYS KEEP AN OPEN MIND.

PLEASE DISCUSS THIS WITH YOUR DOCTOR, SHOULD YOU HAVE ANY QUESTIONS, OR CONCERNS. NEVER DO ANYTHING WITHOUT TALKING TO YOUR DOCTOR FIRST..

I DO NOT MAKE ANY MONEY FROM THIS WEBSITE. I VOLUNTEER MY TIME TO HELP ALL OF US TO BE INFORMED.

I WILL NOT ACCEPT ANY ADVERTISEMENT OR HEALING POWERS, HEALING FROM HERBS AND ETC. UNLESS IT HAS GONE THROUGH TRIALS AND APPROVED BY FDA. IT WILL GO INTO SPAM.

THIS IS A FREE SITE FOR ALL WITH NO ADVERTISEMENTS

THANK YOU FOR VISITING! TOGETHER WE CAN MAKE A DIFFERENCE!

Thursday, March 8, 2018

Parkinson’s startup Prevail raises $75M for gene therapy programs

By Phil Taylor | Mar 8, 2018

Jonathan Silverstein (Silverstein Foundation)

OrbiMed-backed Prevail Therapeutics has launched a $75 million first-round financing that will help fund development of its gene therapy for Parkinson’s disease (PD) and other programs.

Prevail was set up last year by OrbiMed's co-head of private equity Jonathan Silverstein, with seed funding from the investment firm as well as a nonprofit research foundation formed by Silverstein to tackle PD caused by mutations in the glucocerebrosidase (GBA1) gene after he was diagnosed with the illness in 2016.

OrbiMed has participated in the series A financing as well, along with Pontifax Fund, RA Capital Management, EcoR1 Capital, Omega Funds, BVF Partners, Boxer Capital, Adage Capital Management and Alexandria Venture Investments.

Prevail’s co-founder and CEO, Asa Abeliovich, M.D., Ph.D., who is on the faculty of Columbia University and whose lab conducted a chunk of the research underpinning the company’s research programs, said the first round “supports out plan to develop a pipeline of gene therapies with the potential to dramatically improve the lives of patients with a range of genetically defined neurodegenerative diseases.”

The common thread is to target neurodegenerative diseases caused by lysosomal dysfunction, a pathology seen in various forms of PD, including early-onset variants, as well as some types of Alzheimer's disease and frontotemporal dementia.

Prevail has also taken a license to an adeno-associated virus (AAV) gene therapy vector technology developed by Regenxbio called NAV AAV9. This will be used across its gene therapy candidates including lead program PR001, which is being developed for GBA1-linked PD, a variant thought to affect around 10% of all patients with the disease. The hope is that therapies developed for this subset of patients may also have a role more broadly in treating PD.

For now, Prevail isn’t taking about timelines to start trials of PR001 in humans, but a spokesman said the company is “focused on advancing the program as fast as they can.”

https://www.fiercebiotech.com/biotech/parkinson-s-startup-prevail-raises-75m-for-gene-therapy-programs